Legend Biotech Corp (LEGN)
43.74
-1.40
(-3.10%)
USD |
NASDAQ |
Apr 30, 16:00
43.74
0.00 (0.00%)
After-Hours: 20:00
Legend Biotech Research and Development Expense (Quarterly): 105.68M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 105.68M |
| September 30, 2023 | 95.86M |
| June 30, 2023 | 95.79M |
| March 31, 2023 | 84.89M |
| December 31, 2022 | 80.76M |
| September 30, 2022 | 104.52M |
| June 30, 2022 | 68.83M |
| March 31, 2022 | 81.55M |
| December 31, 2021 | 86.50M |
| September 30, 2021 | 72.31M |
| Date | Value |
|---|---|
| June 30, 2021 | 83.46M |
| March 31, 2021 | 71.07M |
| December 31, 2020 | 66.93M |
| September 30, 2020 | 63.66M |
| June 30, 2020 | 53.57M |
| March 31, 2020 | 48.00M |
| December 31, 2019 | 66.10M |
| September 30, 2019 | 41.92M |
| June 30, 2019 | 32.64M |
| March 31, 2019 | 21.29M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
32.64M
Minimum
Jun 2019
105.68M
Maximum
Dec 2023
73.90M
Average
72.31M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Johnson & Johnson | 3.542B |
| Bristol-Myers Squibb Co | 2.695B |
| 2seventy bio Inc | 51.22M |
| Exelixis Inc | 244.67M |
| Alnylam Pharmaceuticals Inc | 272.14M |